AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that the first patient has been dosed in the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported financial results for the first quarter ended March 31, 2016.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, today announced …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported financial results for the full year ended December 31, 2015and provided a business update.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal …
AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, announced an exclusive license agreement in which AVEO has …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that Tuan Ha-Ngoc, after 13 years of service and leadership at AVEO, has stepped down as Chairman and a …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported financial results for the third quarter ended September 30, 2015 and provided a business update.
I’ve been saying this all year. Ultimately, Gilead Sciences, Inc.
